Joel Greenblatt Atea Pharmaceuticals, Inc. Transaction History

Gotham Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $58,314 - $93,367	-10,622 Reduced 48.17%	11,431 $65,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $49,041 - $75,264	-9,201 Reduced 29.44%	22,053 $157,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $11,385 - $19,023	2,070 Added 7.09%	31,254 $226,000
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $114,367 - $664,881	-14,911 Reduced 33.82%	29,184 $261,000
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $463,500 - $761,853	21,730 Added 97.16%	44,095 $1.55 Million
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $429,855 - $1.32 Million	22,365 New	22,365 $480,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.